IN THE UNITED STATES BANKRUPTCY COURT
FOR THE DISTRICT OF DELAWARE

In re:	Chapter 11
SYNTHEGO CORPORATION,[1]	Case No. 25-10823 (MFW)
Debtor.	

NOTICE OF POTENTIAL ASSUMPTION, ASSUMPTION AND ASSIGNMENT, OR TRANSFER OF EXECUTORY CONTRACTS AND UNEXPIRED LEASES

PLEASE TAKE NOTICE OF THE FOLLOWING:

On May 5, 2025 (the "Petition Date"), the above-captioned debtor and debtor in possession (the "Debtor") filed a voluntary petition for relief under chapter 11 of title 11 of the United States Code (the "Bankruptcy Code"). The Debtor is operating its business and managing its property as debtor in possession pursuant to sections 1107(a) and 1108 of the Bankruptcy Code.[2]

On May 29, 2025, the United States Bankruptcy Court for the District of Delaware (the "Court") entered an order (the "Bid Procedures Order"[3]) authorizing the Debtor to establish procedures related to, among other things, the assumption, assumption and assignment, and/or transfer of executory contracts and unexpired leases in connection with a sale of substantially all of the Debtor's assets to be approved by the Court (the "Contract and Lease Procedures").

YOU ARE RECEIVING THIS NOTICE BECAUSE YOU ARE A PARTY TO ONE OR MORE OF THE CONTRACTS OR LEASES REFERRED TO HEREIN.

---

1 The Debtor's mailing address is 3696 Haven Avenue, Suite A, Redwood City, California, 94063, and the last four digits of the Debtor's federal tax identification number is 9518.

2 Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to them in the *Motion for (I) An Order (A) Authorizing Entry Into Asset Purchase Agreement With Respect to the Sale of Substantially All of the Debtor's Assets, (B) Approving Bid Procedures for the Sale of Substantially All of the Debtor's Assets, (C) Scheduling an Auction and Sale Hearing, (D) Approving the Form and Manner of Notice Thereof, (E) Approving Certain Termination Fee and Expense Reimbursement Provisions, and (F) Granting Related Relief; and (II) An Order (A) Approving the Sale of the Debtor's Assets Free and Clear of All Encumbrances, (B) Approving the Assumption and Assignment of Executory Contracts and Unexpired Leases, and (C) Granting Related Relief* [Docket No. 12] (the "Bid Procedures Motion") or Bid Procedures Order (defined below).

3 *Order (A) Authorizing Entry Into Asset Purchase Agreement With Respect to the Sale of Substantially All of the Debtor's Assets, (B) Approving Bid Procedures for the Sale of Substantially All of the Debtor's Assets, (C) Scheduling an Auction and Sale Hearing, (D) Approving the Form and Manner of Notice Thereof, (E) Approving Certain Termination Fee and Expense Reimbursement Provisions, and (F) Granting Related Relief* [Docket No. 97] (the "Bid Procedures Order").

POTENTIAL ASSUMED/ASSIGNED CONTRACTS[4]

Attached as Schedule A is a schedule of all Potential Assumed/Assigned Contracts (the "Cure Schedule") that may be assumed, assumed and assigned, and/or transferred, as applicable, by the Debtor in connection with the Sale, listing the counterparties to such contracts (the "Contract Counterparties") and the amount, if any, proposed to be paid to cure any monetary defaults under the Potential Assumed/Assigned Contracts pursuant to section 365 of the Bankruptcy Code (the "Cure Amounts").[5] **The inclusion of a document on the Cure Schedule is not a commitment that such Potential Assumed/Assigned Contract will, in fact, be assumed by the Debtor, assumed by the Debtor and assigned to a third party, or otherwise transferred by the Debtor to a third party, including in connection with the Sale. The identification of any executory contract or unexpired lease as one that, in connection with a Sale, will, in fact, be assumed by the Debtor, assumed by the Debtor and assigned to a third party, or otherwise transferred to a third party are governed by the Bid Procedures Order.**

IF YOU AGREE WITH THE ASSUMPTION, ASSUMPTION AND ASSIGNMENT, OR TRANSFER OF YOUR POTENTIAL ASSUMED/ASSIGNED CONTRACT(S) AND/OR PROPOSED CURE AMOUNTS LISTED IN **SCHEDULE A** WITH RESPECT TO YOUR POTENTIAL ASSUMED/ASSIGNED CONTRACT(S), YOU ARE NOT REQUIRED TO TAKE ANY FURTHER ACTION.

IF YOU DISAGREE WITH THE ASSUMPTION, ASSUMPTION AND ASSIGNMENT, OR TRANSFER OF YOUR POTENTIAL ASSUMED/ASSIGNED CONTRACT(S) AND/OR THE PROPOSED CURE AMOUNTS LISTED IN **SCHEDULE A** WITH RESPECT TO YOUR POTENTIAL ASSUMED/ASSIGNED CONTRACT(S), YOU MUST OBJECT BY NO LATER THAN **JUNE 20, 2025 AT 5:00 P.M. (PREVAILING EASTERN TIME)** (the "Contract Objection Deadline").

Objections with respect to any Potential Assumed/Assigned Contracts (a "Contract Objection") must be: (i) made in writing and filed on the docket for the Chapter 11 Case no later than the Contract Objection Deadline; (ii) state the basis of such Contract Objection with specificity, including, without limitation, the Cure Amount alleged to be due to such Contract Counterparty, and include complete contact information for such Contract Counterparty (including address, telephone number, and email address); (iii) comply with the Bankruptcy Code, the Bankruptcy Rules, and the Local Rules, and (iv) be served on the following, so as to be actually received by them on or before the Contract Objection Deadline (collectively, the "Notice Parties"):

i. counsel for the Debtor, (a) Fenwick & West, LLP, 902 Broadway, 18th Floor, New York, NY 10010, Attn: Ethan Skerry (eskerry@fenwick.com), and Brendan Montgomery (bmontgomery@fenwick.com); (b) Pachulski Stang Ziehl & Jones LLP, 919 North Market Street, 17th Floor, P.O. Box 8705, Wilmington, DE 19899-8705

[4] The presence of any contract or lease on Schedule A hereto does not constitute an admission that such contract or lease is an executory contract or unexpired lease within the meaning of section 365 of the Bankruptcy Code or that such contract or lease will be assumed and/or assigned by the Debtor.

[5] For avoidance of doubt, the Debtor reserves all rights to remove any executory contract or unexpired lease from the Cure Schedule prior to closing of any sale.

(Courier 19801), Attn: James E. O'Neill (joneill@pszjlaw.com); and (c) Pachulski Stang Ziehl & Jones LLP, One Sansome Street, Suite 3430, San Francisco, CA 94104, Attn: Debra I. Grassgreen (dgrassgreen@pszjlaw.com) and Maxim B. Litvak (mlitvak@pszjlaw.com);

ii. counsel to the Stalking Horse Bidder, (a) Morrison & Foerster LLP, 250 West 55th Street, Floor 20, New York, NY 10019, Attn: James A. Newton, Esq. (jnewton@mofo.com) and Miranda K. Russell, Esq. (mrussell@mofo.com); and (b) Potter Anderson & Corroon LLP, Attn: Christopher M. Samis (csamis@potteranderson.com) and Brett M. Haywood (bhaywood@potteranderson.com);

iii. counsel to the Committee, if any; and

iv. the Office of The United States Trustee, 844 King Street, Suite 2207, Lockbox 35, Wilmington, DE 19801, Attn: Megan Seliber (megan.seliber@usdoj.gov).

Any Contract Counterparty that objects to a Successful Bidder's provision of additional assurance of future performance (the "Adequate Assurance Objection") must file such Adequate Assurance Objection on or before the Sale Hearing and serve such objection on the Notice Parties and the applicable Successful Bidder, or such objecting party may appear and argue at the Sale Hearing. To the extent the parties are unable to resolve an Adequate Assurance Objection, the Court will set a hearing, which may be at the Sale Hearing, on the Adequate Assurance Objection to determine whether terms of the Successful Bid are compliant with section 365 of the Bankruptcy Code in providing adequate assurance of future performance to the Contract Counterparty of the applicable contract or lease.

If you file a Cure Objection or Assumption/Assignment Objection satisfying the requirements herein, the Debtor will confer with you in good faith to attempt to resolve any such Cure Objection or Assumption/Assignment Objection without Bankruptcy Court intervention. If the applicable parties determine that the Cure Objection or Assumption/Assignment Objection cannot be resolved without judicial intervention in a timely manner, the Bankruptcy Court shall resolve such objections (i) at the Sale Hearing scheduled for **June 27, 2025 at 2:00 p.m. (prevailing Eastern Time)** via Zoom and at the United States Bankruptcy Court for the District of Delaware, United States Courthouse, 824 Market Street North, 5th Floor, Courtroom #4, Wilmington, DE 19801, before the Honorable Mary F. Walrath, United States Bankruptcy Judge, or (ii) on such other date subsequent to a Sale Hearing as the Court may designate prior to, during, or after the Sale Hearing (a "Contract Hearing") before the Bankruptcy Court to consider the objection.

If the Debtor identifies additional executory contracts or unexpired leases that it wishes to add to or remove from the Cure Schedule (each an "Additional Contract"), the Debtor shall, as soon as practicable after making such a determination, send an Additional Cure Notice to the applicable Contract Counterparties to such Additional Contracts. To the extent an executory contract or unexpired lease is not assumed, assumed and assigned, or transferred in connection with a Sale, the Debtor may, in its sole discretion, reject such an executory contract or unexpired lease to the extent permitted by law following the Closing.

Objections from any Contract Counterparty to an Additional Contract (an "Additional Contract Objection") must: (i) be made in writing and filed on the docket by the later of (a) the Contract Objection Deadline and (b) seven (7) calendar days after the Debtor files and serves the Additional Cure Notice (as applicable, the "Additional Contract Objection Deadline"); (ii) state the basis of such objection with specificity, including, without limitation, the Cure Amount alleged by such Contract Counterparty, and include contact information for such Contract Counterparty; (iii) comply with the Bankruptcy Code, the Bankruptcy Rules, and the Local Rules; and (iv) be served upon the Notice Parties so as to be actually received by them on or before the Additional Contract Objection Deadline.

If a timely Additional Contract Objection is filed, and cannot be resolved consensually, the Bankruptcy Court shall resolve such Additional Potential Assignment Objection at a hearing to be held (i) on or before seven (7) calendar days from the timely filing of the Additional Potential Assignment Objection; (ii) at the Sale Hearing; or (iii) such other date designated by the Court.

IF YOU FAIL TO TIMELY FILE AND PROPERLY SERVE A CURE OBJECTION OR ASSUMPTION/ASSIGNMENT OBJECTION AS PROVIDED HEREIN (I) YOU WILL BE DEEMED TO HAVE FOREVER WAIVED AND RELEASED ANY RIGHT TO ASSERT A CURE OBJECTION, ASSUMPTION/ASSIGNMENT OBJECTION, OR ADDITIONAL CONTRACT OBJECTION, AS APPLICABLE, AND TO HAVE OTHERWISE CONSENTED TO THE ASSUMPTION, ASSUMPTION AND ASSIGNMENT, OR SALE AND TRANSFER, OF THE DEBTOR'S RIGHT, TITLE, AND INTEREST IN, TO AND UNDER, SUCH POTENTIAL ASSUMED/ASSIGNED CONTRACT OR ADDITIONAL CONTRACT, AS APPLICABLE, ON THE TERMS SET FORTH IN THIS CURE NOTICE AND THE APPLICABLE PURCHASE AGREEMENT, (II) YOU WILL HAVE CONSENTED TO THE ASSUMPTION, ASSUMPTION AND ASSIGNMENT OF, OR SALE AND TRANSFER OF, THE DEBTOR'S RIGHT, TITLE, AND INTEREST IN, TO AND UNDER, ITS POTENTIAL ASSUMED/ASSIGNED CONTRACT, AS THE CASE MAY BE, WITHOUT THE NECESSITY OF OBTAINING ANY FURTHER ORDER OF THE BANKRUPTCY COURT, AND (III) YOU WILL BE BARRED AND ESTOPPED FOREVER FROM ASSERTING OR CLAIMING AGAINST ANY PARTY THAT ANY ADDITIONAL CURE AMOUNTS ARE DUE OR DEFAULTS EXIST, OR CONDITIONS TO ASSUMPTION, ASSUMPTION AND ASSIGNMENT, OR SALE AND TRANSFER, MUST BE SATISFIED, UNDER SUCH POTENTIAL ASSUMED/ASSIGNED CONTRACT.

The Debtor's assumption, assumption and assignment, or sale and transfer, of a Potential Assumed/Assigned Contract is subject to approval by the Bankruptcy Court and consummation of the closing of a Sale. The inclusion of any document on the list of Potential Assumed/Assigned Contracts shall not constitute or be deemed to be a determination or admission by the Debtor that such document is, in fact, an executory contract or unexpired lease within the meaning of the Bankruptcy Code, and all rights with respect thereto are expressly reserved.

The dates set forth in this notice are subject to change, and further notice of such changes may not be provided except through announcements in open court and/or the filing of notices and/or amended agendas. Parties in interest are encouraged to monitor the electronic court docket available at https://dm.epiq11.com/case/synthego/info.

This Notice is subject to the full terms and conditions of the Bid Procedures Order, which shall control in the event of any conflict. The Debtor encourages parties in interest to review such documents in their entirety and consult an attorney if they have questions or want advice.

Dated: June 6, 2025

PACHULSKI STANG ZIEHL & JONES LLP

/s/ James E. O'Neill

Debra I. Grassgreen (admitted *pro hac vice*)
Maxim B. Litvak (admitted *pro hac vice*)
Malhar S. Pagay (admitted *pro hac vice*)
James E. O'Neill (DE Bar No. 4042)
919 North Market Street, 17th Floor
P.O. Box 8750
Wilmington, Delaware 19899-8705
Tel: 302-652-4100
Fax: 302-652-4400
Email: dgrassgreen@pszjlaw.com
mlitvak@pszjlaw.com
mpagay@pszjlaw.com
joneill@pszjlaw.com

Counsel to the Debtor and Debtor in Possession

SCHEDULE A

Schedule of Potential Assumed/Assigned Contracts

SCHEDULE A

Schedule of Potential Assumed/Assigned Contracts

No.	Contract Counterparty	Contract/Lease Title	Date of Contract/Lease	Cure Amount
1	23andMe, Inc.	Research Use Only products	7/21/2023	--
2	4baseio UK, Ltd.	Material Transfer Agreement	4/13/2023	--
3	955 Charter Partners	Lease agreement	4/6/2021	13,000
4	955 Charter Partners	Stormwater Treatment Measures	unknown	--
5	AbbVie, Inc.	Research Use Only products	6/23/2023	--
6	Adaptimmune Limited	GMP like RNA products	5/3/2023	--
7	Akron BioManufacturing, LLC	Manufacturing	10/26/2022	--
8	Anderson Tax LLC	Valuation Services	3/11/2024	--
9	Angela Summers	Consulting	1/6/2025	--
10	Arsenal Biosciences, Inc.	Master agreement for project order services	11/14/2022	--
11	ArsenalBio	GMP sgRNA	3/29/2021	--
12	Aspen Neuroscience, Inc.	Research Use Only products	6/14/2022	--
13	AstraZeneca Pharmaceuticals LP	Master agreement for project order services	1/20/2024	--
14	AstraZeneca Pharmaceuticals LP	Master agreement for project order services	7/12/2023	--
15	AstraZeneca Pharmaceuticals LP	License Agreement	1/1/2025	--
16	AstraZeneca UK Limited	Material Transfer Agreement	8/12/2020	--
17	Avance Biosciences, Inc.	Referral and Co-Marketing Agreement	9/8/2023	--
18	Barton Integration, LLC	Installation & Service Agreement	5/24/2022	--
19	Baylor College of Medicine	GMP RNA products	3/6/2023	--
20	Beam Consulting Company	Managed service support for Salesforce software	10/21/2024	--
21	Beckman Research Institute of the City of Hope	GMP like RNA products	1/8/2021	--
22	Beckman Research Institute of the City of Hope	GMP like RNA products	1/8/2021	--
23	BeiGene (Taiwan) Limited	GMP-like sgRNA	3/27/2023	--
24	Beijing Tee & Howe Law Office	Evaluation Agreement		--
25	Biolegio B.V.	Distributor agreement	2/28/2025	--
26	Bio-Medical Science Co., Ltd.	RNA Reseller Agreement	12/26/2016	--
27	Bit Bio Limited	GMP RNA Products	3/25/2022	--
28	Bit.Bio Ltd.	Research & Development agreement	6/29/2023	--
29	Blueprint Medecines Corporation	Research Use Only products	1/27/2023	--
30	BlueRock Therapeutics LP	Master agreement for project order services	3/15/2021	--
31	BlueRock Therapeutics LP	GMP RNA Products	3/10/2020	--
32	BlueSphere Bio	GMP-like sgRNA	8/30/2021	--
33	Board of Regents of the University of Oklahoma	Clonal Cell Line	9/27/2019	--
34	Bodner Flom Law Offices	Power of attorney	3/29/2022	--
35	California Institute for Regenerative Medecine	Industry resource memorandum of understanding	9/14/2023	--
36	California Institute for Regenerative Medicine	Industry resource memorandum of understanding	9/3/2024	--
37	Cartherics Pty Ltd	GMP-like sgRNA	1/4/2021	--
38	Celularity Inc.	GMP-like sgRNA	4/26/2022	--
39	Charite	GMP RNA Products	7/14/2021	--
40	Chengdu Ucello Biotechnology Co. Limited	GMP like RNA Products	12/11/2023	--
41	Chengdu Ucello Biotechnology Co., Limited	Master agreement for project order services	4/1/2024	--
42	Children's GMP, LLC	Sale & use agreement	6/27/2024	--
43	Chili Piper, Inc.	Sales lead generation	9/30/2024	--
44	Chili Piper, Inc.	Demand Conversion Platform	9/30/2024	--
45	City of Hope	GMP-like sgRNA	1/8/2021	--
46	Clari, Inc.	Groove Core email, calendar, activity tracking & integration	1/7/2025	--
47	Cloudflare	Mutual NDA	1/25/2024	44
48	Config Consultants, LLC	Managed service support for Salesforce software	1/20/2025	--
49	Config Consultants, LLC	Specific services outlined in work order	12/27/2022	--
50	Contentstack Inc.	SaaS	9/2/2022	--
51	Corporate Visions, Inc.	Specific services outlined in SOW	1/6/2022	--
52	Corporate Visions, Inc.	Digital workshop modules for employee training	1/26/2022	--
53	CorrGene Biotechnology Co., Ltd.	GMP like RNA Products	8/15/2022	--
54	CRISPR Therapeutics	GMP like RNA Products	12/15/2020	--
55	CRISPR Therapeutics, Inc.	Research Use Only products	3/10/2021	--
56	Dakewe Biotech Co., Ltd.	non-exclusive distributor agreement	1/6/2020	--
57	Decode Sciences Pty Ltd.	Distributor agreement	2/14/2025	--
58	Degree, Inc. (dba Lattice)	SaaS	7/17/2024	45
59	Dice Therapeutics, Inc.	Research Use Only products	4/14/2023	--
60	Editco Bio, Inc.	Distributor agreement	3/20/2024	492,600
61	Editco Bio, Inc.	Supply & distribution agreement	3/20/2024	--
62	Eggli Properties	Lease agreement	6/28/2018	--
63	Eggli Properties	Lease Agreement Amendment	6/28/2018	--
64	Element Materials Technology Pharma US LLC	Testing, development, and validation services	11/18/202	--
65	EMD Millipore Corporation	Recyclable containers and equipment	8/19/2022	--
66	Emory University	Purchase Order	4/24/2020	--

No.	Contract Counterparty	Contract/Lease Title	Date of Contract/Lease	Cure Amount
67	F. Hoffman LaRoche Ltd	Material Transfer Agreement	7/13/2019	--
68	Fate Therapeutics	Research Use Only products	3/15/2022	--
69	Fathom Video, Inc.	IT software license	3/5/2025	--
70	Fiscal Solutions Ltd.	Tax Services	12/31/2024	--
71	Fisher Scientific Company LLC	Returnable Drum System Agreement	1/1/2025	--
72	Fondazione Telethon ETS	GMP like RNA Products	10/7/2023	--
73	Fu Xin Medical Equipment Co., Ltd.	Distributor agreement	2/12/2025	--
74	Fu Xin Medical Equipment Co., Ltd.	RNA Reseller Agreement	3/17/2017	--
75	Funakoshi Co., Ltd.	non-exclusive distributor agreement	6/1/2017	--
76	Genentech, Inc.	Master agreement for project order services	7/21/2020	--
77	Graphite Bio, Inc.	GMP RNA Products	12/14/2020	--
78	Graphite Bio, Inc.	GMP RNA Products	1/21/2021	--
79	GSL Biotech, Inc. (SnapGene)	Software License Agreement	10/10/2024	--
80	Haven Ave., LLC (Formerly White Properties)	Lease agreement	5/1/2017	544,000
81	Haven Ave., LLC (Formerly White Properties)	Lease Agreement Amendment	5/1/2017	--
82	Haven Ave., LLC (Formerly White Properties)	Lease agreement	7/9/2013	--
83	Haven Ave., LLC (Formerly White Properties)	Lease Agreement Amendment	5/1/2022	--
84	Huidagene Therapeutics PTD LTD	License Agreement	12/26/2023	--
85	HuiGene Therapeutics Co, Ltd.	Research License & Material Transfer Agreement	12/7/2022	--
86	Ingenium Group, LLC	Waste treatment and disposal	6/1/2024	--
87	Institute For Systems Biology	GMP RNA Products	10/31/2024	--
88	Intelletrace, Inc.	Master Services Agreement	10/13/2022	--
89	Jansen Research & Development LLC	Laboratory Service Agreement	8/14/2019	--
90	Jansen Research & Development LLC	Laboratory Service Agreement	11/21/2019	--
91	Jansen Research & Development LLC	Laboratory Service Agreement	6/4/2020	--
92	Jansen Research & Development LLC	Laboratory Service Agreement	6/8/2021	--
93	Jeff Merrick DBA Wireform, LLC	Consulting	3/14/2025	--
94	Kactus Bio, Inc.	Supply Agreement	7/1/2024	--
95	Kactus Bio, Inc.	Supply Agreement	3/1/2025	--
96	Lab-a-Porter Ltd.	Distributor agreement	2/19/2025	--
97	Labospace, S.R.L.	Distributor agreement	3/24/2025	--
98	LeadIQ	Licensed software	12/15/2024	--
99	Leidos Biomedical Research, Inc.	Master agreement for project order services	10/30/2024	--
100	LG CHEM Ltd.	Master agreement for project order services	10/22/2022	--
101	LinkedIn	Sales Navigator software	3/1/2025	--
102	LinkedIn	Software License Agreement	10/7/2024	--
103	LinkSquares, Inc.	SaaS Services	3/19/2024	41,546
104	Lycia Therapeutics, Inc.	Research Use Only products	7/28/2022	--
105	Medical University of Bialystock	Research Agreement	6/16/2020	--
106	Merissa Hamilton	Consulting	11/7/2024	--
107	ModernaTX, Inc.	Master agreement for project order services	10/23/2024	--
108	National Institute of Standards & Technology	Research & Development agreement	9/18/2018	--
109	Nationwide Childrens Hosptal Research Institute	GMP-like sgRNA	5/12/2022	--
110	Neogene Therapeutics, Inc.	Master agreement for project order services	12/9/2022	--
111	Neogene Therapeutics, Inc.	Master agreement for project order services	8/23/2023	--
112	Neogene Therapeutics, Inc.	GMP like RNA Products	4/15/2021	--
113	Nested Therapeutics, Inc.	Research Use Only products	5/11/2022	--
114	Neumora Therapeutics	Research Use Only products	4/18/2023	--
115	Neurocrine Biosciences, Inc.	Research Use Only products	9/18/2023	--
116	Neuvocor Pte. Ltd.	Research Use Only products	8/17/2022	--
117	Nine Square Therapeutics Corporation	Research Use Only products	10/24/2022	--
118	Novo Nordisk	Pharmaceutical services	10/25/2022	--
119	Open Avenues Foundation	Career support programming for foreign nationals	6/16/2023	--
120	Oracle America, Inc.	Netsuite Cloud services	1/20/2025	--
121	Oxford BioTheapeutics LTD	Research Use Only products	2/20/2024	--
122	Pacific Biolabs, Inc.	Specific services outlined in work order	7/25/2024	8,400
123	Packman & Associates, Inc.	Management consulting and executive development services	11/1/2024	--
124	Pact Pharma, Inc.	GMP-like sgRNA	8/28/2020	--
125	Pact Pharma, Inc.	GMP-like sgRNA	12/21/2021	--
126	Pact Pharma, Inc.	GMP-like sgRNA	9/7/2021	--
127	Pangea Inc.	Specific services outlined in work order	10/13/2022	--
128	Pfizer, Inc.	Master agreement for project order services	9/1/2021	--
129	Pfizer, Inc.	Master agreement for project order services	4/1/2023	--
130	PhileKorea Technology, Inc.	Distributor agreement	2/14/2025	--
131	Poseida Therapeutics, Inc.	Research Use Only products	5/16/2023	--
132	Poseida Therapeutics, Inc.	GMB sgRNA	10/1/2021	21,399
133	Poseida Therapeutics, Inc.	GMB sgRNA	9/30/2021	--
134	Prelude Therapeutics, Inc.	Research Use Only products	6/12/2023	--
135	Productiv, Inc.	SaaS	4/22/2022	616
136	Proof Diagnostics, Inc. (Pine Tree Health)	GMP like RNA Products	3/31/2021	--
137	Rebecca Roberts	Consulting	1/1/2025	--
138	Research Institute at Nationwide Children's Hospital	GMP like RNA Products	5/12/2022	--

No.	Contract Counterparty	Contract/Lease Title	Date of Contract/Lease	Cure Amount
139	Rockend Limited	CRISPR SGRNA	4/30/2021	--
140	Ryvu Therapeutics, S.A.	GRNA Products	12/16/2021	--
141	Ryvu Therapeutics, S.A.	GRNA Products	12/10/2021	--
142	Ryvu Therapeutics, S.A.	GRNA Products	6/28/2022	--
143	Salesforce, Inc.	Tableau cloud services / software	3/24/2025	--
144	Salesforce, Inc.	Cloud data services	2/1/2025	--
145	Sana Biotechnology, Inc.	Research Use Only products	11/7/2023	--
146	Sana Biotechnology, Inc.	Master agreement for project order services	6/30/2021	--
147	Sana Biotechnology, Inc.	Master agreement for project order services	12/1/2022	--
148	SAS Biotika	Distributor agreement	1/30/2025	--
149	Science Exchange, Inc.	Master agreement for project order services	1/1/2023	--
150	Scratchpad, Inc.	IT - SAAS forecasting software	10/18/2024	3,744
151	Scripps Research Institute Florida	GMP like RNA Products	11/18/2021	--
152	Servier Pharmaceuticals LLC	Research Use Only products	6/20/2022	--
153	Sifted, LLC	Specific services outlined in Schedule 1	6/4/2024	--
154	Snowflake, Inc.	Training Services	11/13/2024	--
155	SOAProjects, Inc.	Specific services outlined in addendums	3/12/2024	--
156	SRI International	GRNA Products	6/28/2022	--
157	St. Jude Children's Research Hospital	GMP like RNA Products	7/10/2020	--
158	St. Jude Children's Research Hospital	GMP like RNA Products	7/27/2024	--
159	St. Jude Children's Research Hospital	GRNA Products	4/19/2021	--
160	St. Jude Children's Research Hospital	GRNA Products	7/22/2021	--
161	Supreme Optimization, LLC	Digital Marketing Agreement	5/2/2025	--
162	Syserco, Inc.	Software License Agreement	5/1/2024	--
163	Talend, Inc.	SaaS Services	9/10/2024	--
164	The Regents of the University of California	Certification for provision of products	10/18/2022	--
165	The Regents of the University of California	RNA products	6/1/2023	--
166	The Regents of the University of California	Sponsored Research Agreement	8/31/2021	--
167	The Regents of the University of California	GMB sgRNA	7/31/2021	--
168	The Regents of the University of California	GMB sgRNA	7/31/2021	--
169	The Trustees of the University of Pennsylvania	Master agreement for project order services	10/25/2024	--
170	The University of Texas M.D. Anderson Cancer Center	CRISPR SGRNA	12/31/2019	--
171	The University of Texas M.D. Anderson Cancer Center	CRISPR SGRNA	3/24/2021	--
172	T-knife GMBH	Master agreement for project order services	5/21/2024	--
173	T-knife GMBH	Master agreement for project order services	9/19/2024	--
174	Trinet	Service Agreement	unknown	--
175	Ultragenyx Pharmaceutical, Inc.	Research services	2/12/2020	--
176	Ultragenyx Pharmaceutical, Inc.	Master agreement for project order services	2/12/2025	--
177	Universal Janitorial	Janitorial Services	1/1/2025	--
178	University of Vermont	Research Use Only products	12/11/2023	--
179	Validaton Systems, Inc.	Supplier Quality Agreement	11/11/2024	--
180	Vertex Pharmaceuticals, Inc.	RNA synthesis services	12/15/2020	--
181	Vertex Pharmaceuticals, Inc.	RNA synthesis services	12/22/2017	--
182	Vertex Pharmaceuticals, Inc.	GMP like RNA Products	4/22/2022	--
183	Vita Therapeutics, Inc.	Therapeutic sublicense agreement	2/13/2025	--
184	Vita Therapeutics, Inc.	GRNA Products	6/23/2022	--
185	Vivet Therapeutics, SAS	Research Use Only products	3/16/2022	--
186	Vivet Therapeutics, SAS	Non-Clinical Services	9/14/2021	--
187	Waters Technologies Corp.	Laboratory Servicing Agreement	3/1/2025	--
188	Xaira Therapeutics, Inc.	Master agreement for project order services	1/21/2025	--
189	Xap Therapeutics, Inc.	Research Use Only products	6/1/2023	22,255
190	Xap Therapeutics, Inc.	GMP-like sgRNA	6/5/2023	--
191	Y.A. Almog Diagnositc & Medical Equipment, Ltd.	Distributor agreement	2/27/2025	--